Desvenlafaxine

What it is

Desvenlafaxine is the major active metabolite of venlafaxine, sold as an extended-release tablet (as the succinate or fumarate salt) taken once a day. In the United States it is approved only for major depressive disorder in adults. The 50 mg dose is both the starting dose and the therapeutic dose; the 25 mg tablet exists specifically to allow a gradual taper when stopping.

What the research says

For major depressive disorder in adults the evidence supports a modest effect. A systematic review of 17 double-blind trials found a response risk ratio of 1.24 (95% CI 1.16 to 1.32) and remission 1.29 (1.16 to 1.43) against placebo, with dropouts for adverse events almost doubled (RR 1.98, 1.45 to 2.69) - and in head-to-head trials against other antidepressants desvenlafaxine came out slightly worse (response RR 0.90, 0.82 to 0.98). Doses above 50 mg gave no extra benefit and more side effects. It carries the class boxed warning on suicidal thoughts and behaviours in people under 25, failed both of its paediatric trials, and has one of the strongest signals in the literature for discontinuation symptoms: a 2024 Lancet Psychiatry meta-analysis of 21,002 patients named desvenlafaxine among the drugs with both higher frequency and higher severity of discontinuation symptoms.

Evidence grade: Well established.

How it works

Drug class: Serotonin and norepinephrine reuptake inhibitor (SNRI); the active metabolite of venlafaxine

Desvenlafaxine blocks the transporters that pull serotonin and noradrenaline back into nerve endings, so more of both stays in the synapse. It is the molecule venlafaxine turns into in the body. The label is careful to say the exact reason this lifts mood is not known - the reuptake blockade is the measured action, not a proven explanation of the antidepressant effect. (Source 1)

Boxed warning

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.1)]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.1)]. PRISTIQ is not approved for use in pediatric patients [see Use in Specific Populations (8.4)].

(Source 2)

What it is used for

• Modest benefit over placebo across 17 trials (response RR 1.24, remission RR 1.29), with no additional benefit above 50 mg a day. In direct comparisons with other antidepressants it was slightly less effective. Evidence: established. (Source 3)
• Not approved for anyone under 18. Two adequate and well-controlled 8-week placebo-controlled trials in 587 patients aged 7 to 17 failed to show efficacy, and the drug was associated with weight loss (22% and 14% on low and high dose versus 7% on placebo). Evidence: not-supported. (Source 4)
• A four-week phase 3 placebo-controlled trial in 57 women with breast cancer on tamoxifen found both desvenlafaxine doses reduced hot flash scores more than placebo (50 mg: 2.20 points/week, 95% CI 0.71 to 3.68). The trial was small and short, and desvenlafaxine is not FDA-approved for this use. Evidence: limited. (Source 5)

Interactions

• St John's wort (Hypericum perforatum) (label): St John's wort is serotonergic. Taken with desvenlafaxine it adds to serotonin activity and raises the risk of serotonin syndrome. The label names it explicitly in its list of serotonergic drugs to monitor for. (Source 6)
• Tryptophan and 5-HTP-type serotonin precursor supplements (label): Tryptophan is named in the same label list: it feeds serotonin synthesis, so combining it with an SNRI raises serotonin syndrome risk. (Source 6)
• Fish oil, aspirin, NSAIDs and other things that thin the blood (label): SNRIs reduce platelet serotonin and so can increase bleeding risk. The label names NSAIDs, aspirin and warfarin specifically, and tells prescribers to monitor closely for bleeding when desvenlafaxine is started or stopped. We did not find a desvenlafaxine-specific study of fish oil, so grouping it here is an extension of the mechanism, not a documented finding. (Source 6)
• Alcohol (clinical trial): A clinical study found desvenlafaxine did not make alcohol's effect on mental and motor skills worse. The label still advises avoiding alcohol, on general grounds that apply to all CNS-active drugs rather than on a measured interaction. (Source 7)
• Food (label): No food restriction. The label says the dose is taken once daily with or without food, and that tablets must be swallowed whole, not split, crushed, chewed or dissolved, because the extended-release coating controls the release. (Source 8)
• Monoamine oxidase inhibitors, including linezolid and intravenous methylene blue (label): Combination is contraindicated, not merely monitored: the risk is serotonin syndrome. The label sets washout periods of 7 days after stopping desvenlafaxine and 14 days after stopping an MAOI. (Source 6)
• Diuretics, and anything causing volume depletion (label): Desvenlafaxine can cause hyponatremia through inappropriate antidiuretic hormone secretion; diuretics and volume depletion add to that risk, and older people are more vulnerable. (Source 9)
• Drugs metabolised by CYP2D6 (desipramine, atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine) (label): Desvenlafaxine raises the blood levels of these drugs, which can make them toxic. At 100 mg or less the label says no dose change is needed; at 400 mg it says to halve the other drug. (Source 6)

Stopping it

• Desvenlafaxine has a documented discontinuation syndrome. The label lists nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances including electric-shock sensations, tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus and seizures, especially after abrupt stopping. (Source 10)
• The label's own instruction is a gradual reduction, resuming the previous dose if symptoms are intolerable and then going slower - and it states plainly that for some people the taper needs to run over several months. The 25 mg tablet exists for this purpose. (Source 10)
• The 2024 Lancet Psychiatry meta-analysis of 79 studies and 21,002 patients quantified it: 31% of people stopping an antidepressant reported at least one discontinuation symptom versus 17% of people stopping placebo, and severe symptoms occurred in 2.8% versus 0.6%. Desvenlafaxine was named among the drugs with the higher frequencies and, with venlafaxine, among those with higher severity. (Source 11)
• The same review's authors stress that the figures must be read against what happens on placebo, and that residual or returning depression can be mistaken for withdrawal - their net estimate is about 15%, roughly one in six to seven people. (Source 12)
• Desvenlafaxine is not a controlled substance - the label's Controlled Substance section says so - so the discontinuation syndrome is not drug dependence in the legal or addiction sense, but it is a real physiological effect of stopping. (Source 13)

What goes wrong

Dropping out of a trial because of side effects was about twice as likely on desvenlafaxine as on placebo. (Source 3)

• Systematic review, Moderate certainty.
• Size: 17 double-blind randomised controlled trials.
• Who: adults with major depressive disorder.
• How long: acute treatment.
• Result: dropouts due to adverse events RR 1.98 (1.45-2.69, p<0.001)
• Funding: not stated in the abstract.

for dropouts 1.16 (0.99-1.35, p=0.066) and for dropouts due to adverse events 1.98 (1.45-2.69, p<0.001).

The label's commonest adverse reactions were defined as those occurring in at least 5% of people and at least twice the placebo rate, and in the pooled tables they rise steeply with dose. (Source 14)

• Official position, Certainty not rated.
• Size: placebo n=636, 50 mg n=317, 100 mg n=424, 200 mg n=307, 400 mg n=317.
• Who: adults with major depressive disorder.
• How long: 8 weeks.
• Result: Table 2 of the same section gives nausea 10% placebo vs 22% (50 mg), 26% (100 mg), 36% (200 mg), 41% (400 mg); dry mouth 9% vs 11/17/21/25%; constipation 4% vs 9/9/10/14%; hyperhidrosis 4% vs 10/11/18/21%; dizziness 5% vs 13/10/15/16%.
• Funding: regulatory label (manufacturer-submitted data), Wyeth/Pfizer, published 27 April 2026.

The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence ≥ 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.

Across all doses 12% of people on desvenlafaxine stopped for an adverse reaction versus 3% on placebo, but at the recommended 50 mg dose the rate was no different from placebo. (Source 15)

• Official position, Certainty not rated.
• Size: 1,834 patients on desvenlafaxine 50-400 mg and 1,116 on placebo.
• Who: adults with major depressive disorder.
• How long: 8 weeks (one longer study up to 9 months)
• Result: discontinuation for an adverse reaction 12% vs 3% overall; 4.1% at 50 mg vs 3.8% placebo; 8.7% at 100 mg; commonest causes nausea 4%, dizziness, headache and vomiting 2% each.
• Funding: regulatory label (manufacturer-submitted data)

Of the 1,834 patients, 12% discontinued treatment due to an adverse reaction, compared with 3% of the 1,116 placebo-treated patients. At the recommended dose of 50 mg, the discontinuation rate due to an adverse reaction for PRISTIQ (4.1%) was similar to the rate for placebo (3.8%). For the 100 mg dose of PRISTIQ the discontinuation rate due to an adverse reaction was 8.7%.

Pooled FDA analyses of antidepressants found 14 extra cases of suicidality per 1,000 treated in people under 18 and 5 extra per 1,000 in those aged 18 to 24, with fewer cases than placebo in people over 24. (Source 16)

• Meta-analysis, Moderate certainty.
• Size: 24 short-term trials of 9 antidepressants in over 4,400 children and adolescents; 295 short-term trials of 11 antidepressants in over 77,000 adults.
• Who: children, adolescents and adults with major depressive disorder, OCD or other psychiatric disorders.
• How long: short-term, median about 2 months.
• Result: drug-placebo difference in cases of suicidality per 1,000 treated: under 18, +14; 18 to 24, +5; 25 to 64, -1; 65 and over, -6. No suicides occurred in any paediatric study.
• Funding: FDA pooled analyses of manufacturer-submitted trials, reproduced in the label.

Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.

In juvenile rats, desvenlafaxine produced behavioural deficits and, in a second study, delayed sexual maturation and reduced fertility at exposures about twice those of a 100 mg paediatric dose; both reversed after a recovery period. (Source 17)

• Animal study, Very low certainty.
• Size: male and female rats in two juvenile studies.
• Who: juvenile rats dosed from postnatal day 22 (75, 225 and 675 mg/kg/day)
• How long: to postnatal day 112 in the first study; 8 to 9 weeks in the second.
• Result: behavioural deficits in motor activity, straight-channel swimming and acoustic startle, with no No Adverse Effect Level identified and a Low Adverse Effect Level of 75 mg/kg/day, an exposure (AUC) twice that measured with a 100 mg/day paediatric dose; delays in sexual maturation and decreased fertility, implantation sites and live embryos in treated females at all doses; all reversed after a 4-week recovery period.
• Funding: regulatory label (manufacturer-submitted data), Wyeth/Pfizer.

Limit of this finding: This is an animal study. The label itself says the relevance of these findings to humans is not known, and the effects reversed once the rats stopped the drug. It is not evidence that desvenlafaxine does this to children.

Behavioral deficits (longer time immobile in a motor activity test, longer time swimming in a straight channel test, and lack of habituation in an acoustic startle test) were observed in males and females but were reversed after a recovery period.

Roughly a third of people stopping an antidepressant report at least one discontinuation symptom, against about a sixth stopping placebo; desvenlafaxine was among the drugs with the highest frequency and severity. (Source 11)

• Systematic review, Moderate certainty.
• Size: 21,002 patients across 79 studies (44 RCTs, 35 observational); 16,532 discontinued an antidepressant and 4,470 a placebo.
• Who: people with any mental, behavioural or neurodevelopmental disorder, 72% female, mean age 45.
• How long: varies; cessation or tapering studies to October 2022.
• Result: at least one discontinuation symptom 0.31 (95% CI 0.27-0.35) after antidepressant vs 0.17 (0.14-0.21) after placebo; RCT summary difference 0.08 (0.04-0.12); severe symptoms 0.028 (0.014-0.057) vs 0.006 (0.002-0.013). Heterogeneity was substantial.
• Funding: none (stated in the paper)

Limit of this finding: Two numbers in this paper look like they disagree and do not. The roughly 15% net figure compares everyone stopping an antidepressant (31%) with everyone stopping placebo (17%) across all the study designs included. The 0.08 difference comes only from the randomised trials, where both groups were followed in the same way. They answer different questions, so neither corrects the other, and they should not be presented as two readings of one quantity.

Desvenlafaxine, venlafaxine, imipramine, and escitalopram were associated with higher frequencies of discontinuation symptoms, and imipramine, paroxetine, and either desvenlafaxine or venlafaxine were associated with a higher severity of symptoms.

After subtracting what happens when people stop a placebo, the net incidence of antidepressant discontinuation symptoms is about 15%, or one in six to seven people. (Source 12)

• Systematic review, Moderate certainty.
• Size: 21,002 patients across 79 studies.
• Who: people discontinuing an antidepressant or placebo.
• How long: varies.
• Result: net incidence approximately 15%; severe symptoms about 2.8% on antidepressant vs 0.6% on placebo.
• Funding: none (stated in the paper)

Limit of this finding: Two numbers in this paper look like they disagree and do not. The roughly 15% net figure compares everyone stopping an antidepressant (31%) with everyone stopping placebo (17%) across all the study designs included. The 0.08 difference comes only from the randomised trials, where both groups were followed in the same way. They answer different questions, so neither corrects the other, and they should not be presented as two readings of one quantity.

Considering non-specific effects, as evidenced in placebo groups, the incidence of antidepressant discontinuation symptoms is approximately 15%, affecting one in six to seven patients who discontinue their medication.

Desvenlafaxine can raise blood pressure enough to need treatment, and the label requires regular monitoring. (Source 18)

• Official position, Certainty not rated.
• Size: not quantified in this section.
• Who: all adults taking the drug, especially those with existing hypertension or cardiovascular disease.
• How long: ongoing.
• Result: increases in blood pressure observed in clinical studies; cases requiring immediate treatment reported; no rates given in this section.
• Funding: regulatory label (manufacturer-submitted data)

Cases of elevated blood pressure requiring immediate treatment have been reported with PRISTIQ. Sustained blood pressure increases could have adverse consequences.

Hyponatremia, sometimes severe, is a recognised harm, with serum sodium below 110 mmol/L reported. (Source 9)

• Case series, Very low certainty.
• Size: not quantifiable - post-marketing and trial case reports.
• Who: people taking SSRIs or SNRIs; elderly people, those on diuretics and those volume-depleted are at greater risk.
• How long: ongoing.
• Result: cases with serum sodium lower than 110 mmol/L reported; severe cases have included hallucination, syncope, seizure, coma, respiratory arrest and death.
• Funding: regulatory label (manufacturer-collected reports)

Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs.

The label records post-marketing reports of serious, protracted discontinuation symptoms, including completed suicide and severe aggression during dose reduction. (Source 10)

• Case series, Very low certainty.
• Size: not quantifiable - spontaneous post-marketing reports.
• Who: people stopping or reducing desvenlafaxine.
• How long: symptoms described as sometimes protracted, with tapering sometimes needing several months.
• Result: no rates; reported events include nausea, sweating, dysphoric mood, electric-shock sensations, tremor, seizures, visual changes, raised blood pressure, completed suicide, suicidal thoughts and severe aggression.
• Funding: regulatory label (manufacturer-collected spontaneous reports)

There have been postmarketing reports of serious discontinuation symptoms with PRISTIQ, which can be protracted and severe. Completed suicide, suicidal thoughts, and severe aggression (including hostility, rage, and homicidal ideation) have been observed in patients during reduction in PRISTIQ dosage, including during discontinuation.

What the evidence supports

Desvenlafaxine beat placebo for response and remission in major depression, but the effect sizes were moderate and no dose did better than another. (Source 3)

• Systematic review, Moderate certainty.
• Size: 17 double-blind randomised controlled trials.
• Who: adults with major depressive disorder.
• How long: acute treatment (8 weeks in most of the pooled trials)
• Result: response RR 1.24 (1.16-1.32, p<0.001); remission RR 1.29 (1.16-1.43, p<0.001); overall dropouts RR 1.16 (0.99-1.35, p=0.066); no differences between 50, 100, 200 and 400 mg.
• Funding: not stated in the abstract; most desvenlafaxine registration trials were manufacturer-sponsored.

In the placebo-controlled trials the overall risk ratio for response was 1.24 (1.16-1.32, p<0.001), for remission 1.29 (1.16-1.43, p<0.001), for dropouts 1.16 (0.99-1.35, p=0.066) and for dropouts due to adverse events 1.98 (1.45-2.69, p<0.001).

Desvenlafaxine reduced hot flashes more than placebo in women with breast cancer taking tamoxifen, in a small short trial. (Source 5)

• Randomized trial, Low certainty.
• Size: 57 women randomised to three arms.
• Who: women aged 19 or over on adjuvant tamoxifen with moderate-to-severe hot flashes for more than a month.
• How long: 4 weeks.
• Result: hot flash score reduction vs placebo: 50 mg 2.20 points/week (95% CI 0.71 to 3.68); 100 mg 2.34 points/week (95% CI 0.92 to 3.76)
• Funding: not stated in the abstract; ClinicalTrials.gov NCT02819921.

Limit of this finding: The paper calls itself a phase 3 trial but randomised only 57 women across three arms, which is the size of a phase 2 study. Read it as a small, short, early signal rather than the large confirmatory trial that 'phase 3' usually implies.

Both desvenlafaxine arms demonstrated greater HF score reductions compared to placebo: D-50 (2.20 points/week, 95% CI: 0.71, 3.68) and D-100 (2.34 points/week, 95% CI: 0.92, 3.76).

What the evidence does not support

In head-to-head trials against other antidepressants, desvenlafaxine was slightly less effective, not more. (Source 3)

• Systematic review, Low certainty.
• Size: head-to-head subset of the 17 pooled trials.
• Who: adults with major depressive disorder.
• How long: acute treatment.
• Result: response RR 0.90 (0.82-0.98, p=0.014); remission RR 0.82 (0.71-0.95, p=0.009), both favouring the comparator antidepressant.
• Funding: not stated in the abstract.

The mean risk ratio for response in the head-to-head trials was 0.90 (0.82-0.98, p=0.014) and for remission 0.82 (0.71-0.95, p=0.009).

The review's authors concluded the effect was moderate and that desvenlafaxine may be less effective than other antidepressants. (Source 19)

• Systematic review, Low certainty.
• Size: 17 trials.
• Who: adults with major depressive disorder.
• How long: acute treatment.
• Result: authors' overall judgement, no new numbers.
• Funding: not stated in the abstract.

The risk ratios for response and remission were moderate. We further provide some evidence that desvenlafaxine might not be as efficacious as other antidepressants.

Desvenlafaxine failed to show efficacy in both of its paediatric depression trials and was associated with weight loss in children. (Source 4)

• Randomized trial, Moderate certainty.
• Size: 587 patients aged 7 to 17 across two trials.
• Who: children and adolescents with major depressive disorder.
• How long: 8 weeks, with 6-month open-label extensions.
• Result: efficacy not demonstrated in two adequate and well-controlled placebo-controlled trials; weight loss of 3.5% or more of baseline weight in 22% (low dose), 14% (high dose) and 7% (placebo)
• Funding: regulatory label (manufacturer-submitted data)

Efficacy was not demonstrated in two adequate and well controlled, 8-week, randomized, double-blind, placebo-controlled, parallel group studies conducted in 587 patients (7 to 17 years of age) for the treatment of MDD.

Pooled trial data found no overall effect of desvenlafaxine on sexual dysfunction compared with placebo, which conflicts with the label's warning. (Source 20)

• Meta-analysis, Low certainty.
• Size: 1,562 patients at week 8, pooled from three randomised double-blind placebo-controlled trials.
• Who: adult outpatients with major depressive disorder.
• How long: 8 weeks.
• Result: sexual dysfunction rates 54% (50 mg), 47% (100 mg) and 49% (placebo); adjusted odds ratios vs placebo 1.205 (0.928, 1.564) and 1.129 (0.795, 1.604); treatment-by-baseline-sexual-dysfunction interaction P=0.0663.
• Funding: post-hoc analysis of manufacturer trials (industry-sponsored source data)

Limit of this finding: This abstract contradicts itself two sentences apart: it says treatment-by-sex interactions were not statistically significant, and then that small but statistically significant interactions were seen for sex drive (P=0.0011) and ease of erection or lubrication (P=0.0151). It never says which analysis each sentence refers to, so nothing about men versus women should be concluded from it. Two further cautions: the raw rate of sexual dysfunction on 100 mg (47%) was lower than on placebo (49%) while the adjusted odds ratio points the other way; and although the paper is titled a meta-analysis, what it describes is a post-hoc pooled analysis of patient data from three trials.

At week 8, last observation carried forward (n=1562), SD rates were 54, 47, and 49% for 50 mg/day desvenlafaxine, 100 mg/day desvenlafaxine, and placebo, respectively

Where the research disagrees

Whether desvenlafaxine causes sexual dysfunction

• FDA label (Wyeth/Pfizer, published 27 April 2026), regulatory position based on adverse reaction reports and trial data: In male patients, SNRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SNRI use may result in decreased libido and delayed or absent orgasm. (Source 21)
• Pooled post-hoc analysis of three placebo-controlled trials (Int Clin Psychopharmacol 2015), post-hoc meta-analysis of 1,562 patients using the Arizona Sexual Experiences Scale at 8 weeks: Although there was no overall effect of desvenlafaxine on SD, a treatment by baseline SD interaction was suggested for 100 mg desvenlafaxine. (Source 20)

How much discontinuation symptoms should worry someone stopping desvenlafaxine

• FDA label, Discontinuation Syndrome section, spontaneous post-marketing reports; no rates calculable: There have been postmarketing reports of serious discontinuation symptoms with PRISTIQ, which can be protracted and severe. (Source 10)
• Henssler et al., Lancet Psychiatry 2024, systematic review and meta-analysis of 79 studies, 21,002 patients, with placebo comparison: our findings can inform clinicians and patients about the probable extent of antidepressant discontinuation symptoms without causing undue alarm. (Source 12)

How much

• Reference intake: Dosing is set by the prescriber. As a position, the Pristiq label (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer, published 27 April 2026) states that the recommended dose is 50 mg once daily, with or without food, and that 50 mg is both the starting dose and the therapeutic dose. (Source 8)
• Upper limit: As a position, the same label states that doses of 50 mg to 400 mg a day were shown to be effective but that no additional benefit was demonstrated above 50 mg a day, with more adverse reactions and discontinuations at higher doses. There is no population reference intake or upper intake level - this is a prescription medicine, not a nutrient. (Source 8)
• Studied: The label states that doses of 10 mg to 400 mg a day were studied in clinical trials. (Source 8)
• Studied: The 2015 systematic review found no differences between the 50, 100, 200 and 400 mg doses used across 17 trials. (Source 3)
• Studied: The breast cancer hot flash trial randomised women to desvenlafaxine 50 mg/day, 100 mg/day or placebo for four weeks. (Source 5)

A common belief, and what the research shows

The belief: Desvenlafaxine is a newer, stronger version of venlafaxine, so it works better.

What the research shows: It is not a new molecule at all - it is the metabolite venlafaxine becomes in the body. In direct comparisons it did slightly worse, not better: the systematic review of 17 trials reports "The mean risk ratio for response in the head-to-head trials was 0.90 (0.82-0.98, p=0.014)" and concludes "desvenlafaxine might not be as efficacious as other antidepressants". Nor is higher dosing stronger: the label states "no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses".

Questions and answers

What is it?

Desvenlafaxine is an extended-release antidepressant tablet taken once a day. Chemically it is the active metabolite that venlafaxine turns into in the body, sold in its own right as the succinate or fumarate salt. In the United States it is approved only for major depressive disorder in adults. (Source 22)

What does it do in the body?

It blocks the reuptake transporters for serotonin and noradrenaline, so both neurotransmitters stay in the synapse longer. That is the measured pharmacology; the label is careful to say the reason this relieves depression is not actually known. (Source 1)

Is it good or bad for you?

For adults with major depression it does more good than harm on average, but modestly: across 17 trials it raised response and remission rates (RR 1.24 and 1.29) while nearly doubling dropouts from side effects, and in head-to-head trials it was slightly worse than other antidepressants. For children and adolescents it is neither approved nor effective in its own trials, and it carries the class boxed warning on suicidal thoughts in people under 25. Stopping it is harder than with most antidepressants. (Source 3)

How do you get more of it?

Desvenlafaxine is prescription-only; no food, supplement or behaviour supplies it. Dose is the prescriber's decision, and the evidence argues against assuming more is better: 50 mg is both the starting and the therapeutic dose, doses up to 400 mg were studied, and no extra benefit appeared above 50 mg while side effects and discontinuations rose. (Source 8)

If it is harmful, what reduces it?

There is no antidote and no way to flush it out - the label says no specific antidotes are known and management of overdose is supportive. Reducing the amount in the body is done by tapering the dose, which is itself the hard part: the 25 mg tablet exists to allow a gradual reduction, and the label warns that for some people the taper has to run over several months. (Source 8)

Why might someone be low in it or missing it?

Nobody is naturally low in desvenlafaxine; it is a medicine, not a nutrient. People come off it because of side effects - 12% stopped for an adverse reaction across the pooled trials versus 3% on placebo, though at the recommended 50 mg dose that rate was no different from placebo - because it stopped working, or because they and their prescriber decided to taper. Abrupt loss of supply is a particular problem with this drug because of its discontinuation syndrome. (Source 15)

Which whole foods contain it or feed it?

No whole food contains desvenlafaxine or feeds it. The food facts that matter are practical: it can be taken with or without food, and the tablet must be swallowed whole rather than split, crushed, chewed or dissolved, because breaking the extended-release shell would release the whole dose at once. (Source 8)

What happens if you do not have it?

Nothing happens to someone who has never taken it. For someone already on it, stopping is the risk: about 31% of people stopping an antidepressant report at least one discontinuation symptom against 17% stopping placebo, with severe symptoms in about 2.8% versus 0.6%, and desvenlafaxine sits among the drugs with both higher frequency and higher severity. Depression itself can also return, which the reviewers note can look like withdrawal. (Source 11)

How can you test for it?

There is no blood test for whether desvenlafaxine is needed or working - diagnosis and response are judged clinically, with depression rating scales in trials. The tests that matter are safety tests: blood pressure, which the label requires to be monitored regularly because increases were seen in trials, and serum sodium, since hyponatremia severe enough to reach below 110 mmol/L has been reported. (Source 18)

References

1. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 12.1 Mechanism of Action. 2026. Read the source
2. DailyMed / Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section WARNING: SUICIDAL THOUGHTS AND BEHAVIORS (boxed warning, Full Prescribing Information body text). 2026. Read the source
3. Pharmacopsychiatry. Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis - abstract section: Results. 2015. PMID 26205685, DOI 10.1055/s-0035-1555879. Read the source
4. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 8.4 Pediatric Use: human paediatric data. 2026. Read the source
5. npj Breast Cancer. Differential effects of desvenlafaxine on hot flashes in women with breast cancer taking tamoxifen: a randomized controlled trial - full abstract (unstructured). 2024. PMID 39019875, DOI 10.1038/s41523-024-00668-w. Read the source
6. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 7.1 Drugs Having Clinically Important Interactions with PRISTIQ. 2026. Read the source
7. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 7.3 Alcohol. 2026. Read the source
8. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 2.1 General Instructions for Use. 2026. Read the source
9. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 5.9 Hyponatremia. 2026. Read the source
10. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 5.7 Discontinuation Syndrome. 2026. Read the source
11. The Lancet Psychiatry. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis - abstract section: Findings. 2024. PMID 38851198, DOI 10.1016/s2215-0366(24)00133-0. Read the source
12. The Lancet Psychiatry. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis - abstract section: Interpretation. 2024. PMID 38851198, DOI 10.1016/s2215-0366(24)00133-0. Read the source
13. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 2.5 Discontinuing PRISTIQ. 2026. Read the source
14. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 6.1 Clinical Studies Experience, Common Adverse Reactions subsection with Table 2. 2026. Read the source
15. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 6.1 Clinical Studies Experience, Adverse Reactions Reported as Reasons for Discontinuation of Treatment subsection. 2026. Read the source
16. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 5.1 Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients. 2026. Read the source
17. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 8.4 Pediatric Use: Juvenile Animal Studies subsection. 2026. Read the source
18. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 5.3 Elevated Blood Pressure. 2026. Read the source
19. Pharmacopsychiatry. Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis - abstract section: Discussion. 2015. PMID 26205685, DOI 10.1055/s-0035-1555879. Read the source
20. International Clinical Psychopharmacology. Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis - full abstract (unstructured). 2015. PMID 26230270, DOI 10.1097/yic.0000000000000094. Read the source
21. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 5.11 Sexual Dysfunction. 2026. Read the source
22. DailyMed / Wyeth Pharmaceuticals LLC (SPL version 67, label effectiveTime 28 April 2026; DailyMed publication date 27 April 2026). PRISTIQ (desvenlafaxine succinate) extended-release tablet - FDA label, section 1 INDICATIONS AND USAGE. 2026. Read the source